Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

Core Insights - Collegium Pharmaceutical, Inc. is presenting real-world data on its ADHD treatment Jornay PM at the NAPNAP conference, highlighting its commitment to improving patient outcomes [1][2] Company Overview - Collegium Pharmaceutical is focused on developing differentiated medicines for serious medical conditions, with Jornay PM as a key product in its portfolio [2][15] - The company aims to grow its commercial portfolio and establish a presence in neuropsychiatry through the acquisition of Jornay PM [15] Product Information - Jornay PM is a central nervous system stimulant indicated for the treatment of ADHD in patients aged six years and older [5][14] - The product is designed to help increase attention and decrease impulsiveness and hyperactivity in individuals with ADHD [14] Conference Details - The NAPNAP 46 National Conference on Pediatric Health Care is being held in Chicago from March 10-13, 2025, where Collegium will showcase two poster presentations [1][3] - The posters will cover real-world persistence and adherence, as well as utilization data for delayed-release/extended-release methylphenidate from a large US claims database [3]